Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 231
Tipo Título / Nombre Autor(es) Año
Nationwide Laboratory Network for AML Cross-Validated NGS Studies: Results from a Real-Life Cohort of the Pethema Group Sargas C, Ayala R, Cillon C, Larrayoz MJ..., Bergua JM 2021
Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries Recher C, Rolling C, Berard E, Bertoli S..., Bergua JM 2021
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E..., Bergua Burgués JM 2021
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY..., Bergua J 2021
NPM1+ /FLT3- Acute Myeloid Leukemia after JAK2-V617F+ Essential Thrombocythemia. Management and Prognosis Moriano B, Barragan E, Ferré O, Casas I, Prieto Fernández J, Hernández C, Cáceres S, Suárez S, Cardesa R, Arcos MJ, Bañas H, Bergua JM 2021
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M..., Bergua Burgués JM 2021
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group Palanques-Pastor T, Megías-Vericat JE, Martínez P, López Lorenzo JL, Cornago Navascués J..., Bergua Burgués JM 2021
Frequency, clinical characteristics and outcome of adults with acutelymphoblastic leukemia and COVID 19 infection in the first vs.second pandemic wave in Spain Ribera JM, Morgades M, Coll R, Barba P, López-Lorenzo JL..., Bergua J, Sánchez Sánchez MJ, Mateos MC, Piñana JL 2021
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the PETHEMA-FLUGAZA phase 3 clinical trial Ayala R, Rapado I, Onecha E, Martínez-Cuadrón D, Carreño-Tarragona G, Bergua JM, Vives S, Algarra JL, Tormo M, Martinez P, Serrano J, Herrera P, Salamero O, Lavilla E, Gil C, López Lorenzo JL, Vidriales MB, Labrador J, Falantes JF, Sayas MJ, Paiva B, Barragán E, Prosper F, Sanz MÁ, Martínez-López J, Montesinos P, On Behalf Of The Programa Para El Estudio de la Terapeutica En Hemopatias Malignas Pethema Cooperative Study Group 2021
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients Martínez Sánchez MP, Megías-Vericat JE, Rodríguez-Veiga R, Vives S, Bergua JM, Torrent A, Suárez-Varela S, Boluda B, Martínez-López J, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Martín-Herreros B, Serrano A, Sempere A, Barragán E, Sargas C, Sanz M, Martínez-Cuadrón D, Montesinos P, PETHEMA group 2021